SOURCE: Medistem Laboratories

February 22, 2008 10:05 ET

Medistem and Collaborators Publish Arthritis Paper

SCOTTSDALE, AZ--(Marketwire - February 22, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM) (Frankfurt: S2U) announced today the publication of a paper entitled "Antigen-specific therapy of rheumatoid arthritis" in the February issue of the peer-reviewed journal Expert Opinion on Biological Therapies. The article, which was written by scientists at Medistem, the University of Western Ontario, and the University of Toronto, describes methods of selectively inhibiting pathological immune responses in arthritis patients. An abstract of the article may be found at http://www.expertopin.com/doi/abs/10.1517/14712598.8.2.191.

"The importance of immunology in any stem cell endeavor can not be underestimated. By working with internationally renowned scientists such as Dr. Wei-Ping Min, Medistem seeks to not only regenerate injured tissue in diseases such as rheumatoid arthritis, but also to stop the original cause of the injury; that cause being a misguided immune response against proteins in the joints," said Thomas Ichim, the first author of the paper and Medistem's Chief of Scientific Development.

Medistem's lead product, a menstrual blood derived stem cell termed the endometrial regenerative cell (ERC), appears to possess the ability to modulate pathological immune responses, and is currently undergoing investigative tests.

"Currently, the majority of treatment approaches for pathological immune responses involve non-specific immune suppression. This causes potential side effects such as increased risks of viral and bacterial infections," said Dr. Wei-Ping Min, the senior author of the paper. "Understanding and manipulating the molecular mechanisms that activate self-reactive responses provides a potential means of logically addressing the problem of autoimmunity."

About Medistem

Medistem Laboratories is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into all major tissue types of the body, produce high amounts of growth factors, and has astonishing replicative ability. Due to Medistem's relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information